 |
answer text |
<p>NHS England has considered a policy for Kuvan (sapropterin) at the Clinical Priorities
Advisory Group (CPAG) meeting on 6/7 November. Whilst NHS England did make an estimate
of the current cost of protein supplements and a potential reduction in their use
if Kuvan were prescribed, this cost was not included in the analysis because commissioning
responsibility for supplements rests with clinical commissioning groups and it would
be unlikely that NHS England would be able to realise these savings. The cost of the
potential reduction in protein supplements is also relatively modest compared to the
cost of Kuvan.</p><p> </p><p>In line with its published process, the recommendations
from CPAG will be considered by the Specialised Commissioning Oversight Group and
the Specialised Services Commissioning Committee. A decision about whether or not
Kuvan has been prioritised for funding will be published in due course.</p><p> </p><p>The
National Institute for Health and Care Excellence (NICE) is currently developing technology
appraisal guidance for the National Health Service on the use of Kuvan for the treatment
of phenylketonuria. In developing technology appraisal guidance, NICE takes into account
all the health and publicly funded social care related costs and benefits associated
with the treatment, potentially including any costs from NHS funded treatments that
can be avoided such as food supplements. The NICE appraisal of Kuvan is now underway
and NICE expects to publish final guidance next year.</p>
|
|
